<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Division of Pathology</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/9B855EFE-01C4-4EC2-9E29-A842C94C30C2"><gtr:id>9B855EFE-01C4-4EC2-9E29-A842C94C30C2</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:otherNames>Edward</gtr:otherNames><gtr:surname>Cheetham</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0401350"><gtr:id>EF1157A4-E6F3-48D9-98B3-F9DA2A0BEE65</gtr:id><gtr:title>The role of a neuronal chaperone protein in neurodegeneration</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0401350</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2007-08-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>208815</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London (UCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>UCL Institute of Neurology</gtr:department><gtr:description>ALS collaboration</gtr:description><gtr:id>8DBCE4E8-E487-48C8-AC0B-6D0B84061FA2</gtr:id><gtr:impact>The publications are described in another entry for grant G0700412</gtr:impact><gtr:partnerContribution>We have gained support from MNDA to look at the effect of chaperone manipulation on the pathogenesis of the G93A model of ALS.</gtr:partnerContribution><gtr:piContribution>We provided transgenic mice to make the study possible</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>EMBO Chaperone conference</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>78BA1BB8-AE89-42E7-8B3D-50238748E9AC</gtr:id><gtr:impact>We presented the generation of our genetically modified mouse models so that the wider chaperone community were aware they were available.

The work was well received.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BSCB/BSDB 2008 meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>747048AD-9F8F-475E-9C34-E67DC8E2FF76</gtr:id><gtr:impact>Our data on molecular chaperone manipulation of tau aggregation was presented as a platform presentation to an international audience.

The presentation was well received</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MNDA 19th International Symposium</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>44204652-D9FC-4AE9-95CE-27BF482C57E0</gtr:id><gtr:impact>Our data on the role of chaperones in ALS was presented as a platform presentation to an international audience

The presentation was well received and initiated a collaboration</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>73000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MNDA PhD Studentship</gtr:description><gtr:end>2009-10-02</gtr:end><gtr:fundingOrg>Motor Neurone Disease Association (MND)</gtr:fundingOrg><gtr:id>77F51800-E1DE-44C8-A0C6-69CE2F58C66C</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>465000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Project Grant</gtr:description><gtr:end>2010-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>8BC973FB-144A-427B-99FE-61FF3C355614</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Transgenic mice with altered levels of chaperone proteins</gtr:description><gtr:id>6435A7B0-2C22-4799-94EB-32DED4BD5E4F</gtr:id><gtr:impact>These transgenic mice are proving important for our understanding of neurodegenerative disease</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Chaperone transgenics</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>New transgenic mice with ablated or increased molecular chaperone expression</gtr:description><gtr:id>EA115060-4195-41D9-94D1-CBC18B32381F</gtr:id><gtr:impact>These are valuable tools for probing the biology of molecular chaperones and their role in disease.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>HSJ1 transgenics</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have developed cell models for Alzheimer's Parkinson's, ALS, retinitis pigmentosa and Huntington's disease</gtr:description><gtr:id>A0299A14-D74C-400F-9767-668172D792D4</gtr:id><gtr:impact>We have distributed and received reagents for these cell models that are advancing our understanding of neurodegenerative disease.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Cell models of neurodegeneration</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AA29E07E-4189-4FE1-AE6B-C2B9DA5DF9D0"><gtr:id>AA29E07E-4189-4FE1-AE6B-C2B9DA5DF9D0</gtr:id><gtr:title>Hsp40 molecules that target to the ubiquitin-proteasome system decrease inclusion formation in models of polyglutamine disease.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/885ef99b53691af953b962d6526bd16b"><gtr:id>885ef99b53691af953b962d6526bd16b</gtr:id><gtr:otherNames>Howarth JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/40FDF756-7F48-4024-A4B1-27D198C68DD3"><gtr:id>40FDF756-7F48-4024-A4B1-27D198C68DD3</gtr:id><gtr:title>DnaJB6 is present in the core of Lewy bodies and is highly up-regulated in parkinsonian astrocytes.</gtr:title><gtr:parentPublicationTitle>Journal of neuroscience research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8958c09e49ef3fc800fb067584f5420e"><gtr:id>8958c09e49ef3fc800fb067584f5420e</gtr:id><gtr:otherNames>Durrenberger PF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0360-4012</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/300E2884-27B5-4550-806D-C391EE210A8A"><gtr:id>300E2884-27B5-4550-806D-C391EE210A8A</gtr:id><gtr:title>Molecular chaperone-mediated rescue of mitophagy by a Parkin RING1 domain mutant.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/22ea6f41ebff3ca3ff06c86954855e1e"><gtr:id>22ea6f41ebff3ca3ff06c86954855e1e</gtr:id><gtr:otherNames>Rose JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/187D4F39-CC3B-44EB-9C15-D3CBC2E35A63"><gtr:id>187D4F39-CC3B-44EB-9C15-D3CBC2E35A63</gtr:id><gtr:title>Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1 mouse model of ALS.</gtr:title><gtr:parentPublicationTitle>Journal of neurochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/51fb847e6a36c4c4664cccb152cf38ba"><gtr:id>51fb847e6a36c4c4664cccb152cf38ba</gtr:id><gtr:otherNames>Kalmar B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-3042</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/32F8AC77-750D-46E5-BA98-8BABDD8466E3"><gtr:id>32F8AC77-750D-46E5-BA98-8BABDD8466E3</gtr:id><gtr:title>Cytosolic and ER J-domains of mammalian and parasitic origin can functionally interact with DnaK.</gtr:title><gtr:parentPublicationTitle>The international journal of biochemistry &amp; cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bdf978f657c0c69e62311456e4e8a347"><gtr:id>bdf978f657c0c69e62311456e4e8a347</gtr:id><gtr:otherNames>Nicoll WS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1357-2725</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/50FCC3B8-0B37-4318-9813-2955C5A6BFF2"><gtr:id>50FCC3B8-0B37-4318-9813-2955C5A6BFF2</gtr:id><gtr:title>Molecular chaperones and photoreceptor function.</gtr:title><gtr:parentPublicationTitle>Progress in retinal and eye research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/eeab131b3d69e24baab007050733e072"><gtr:id>eeab131b3d69e24baab007050733e072</gtr:id><gtr:otherNames>Kosmaoglou M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1350-9462</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/808F02DD-D803-4716-883F-CDB379589741"><gtr:id>808F02DD-D803-4716-883F-CDB379589741</gtr:id><gtr:title>Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/afb2847081d0754d1285bc82fbcc2bc5"><gtr:id>afb2847081d0754d1285bc82fbcc2bc5</gtr:id><gtr:otherNames>Borrell-Pag?s M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0401350</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>